Literature DB >> 15619107

Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats.

Marcello Solinas1, Steven R Goldberg.   

Abstract

RATIONALE: Many behavioral effects of delta-9-tetrahydrocannabinol (THC), including its discriminative-stimulus effects, are modulated by endogenous opioid systems.
OBJECTIVE: To investigate opioid receptor subtypes involved in the discriminative effects of THC.
METHODS: Rats trained to discriminate 3 mg/kg i.p. of THC from vehicle using a two-lever operant drug-discrimination procedure, were tested with compounds that bind preferentially or selectively to either mu-, delta- or kappa-opioid receptors.
RESULTS: The preferential mu-opioid receptor agonist heroin (0.3-1.0 mg/kg, i.p.), the selective delta-opioid receptor agonist SNC-80 (1-10 mg/kg, i.p.) and the selective kappa-opioid receptor agonist U50488 (1-10 mg/kg, i.p.) did not produce generalization to the discriminative effects of THC when given alone. However, heroin, but not SNC-80 or U50488, significantly shifted the dose-response curve for THC discrimination to the left. Also, the preferential mu-opioid receptor antagonist naltrexone (0.1-1 mg/kg, i.p.), the selective delta-opioid receptor antagonist, naltrindole (1-10 mg/kg, i.p.) and the kappa-opioid receptor antagonist nor-binaltorphimine (n-BNI, 5 mg/kg, s.c.), did not significantly reduce the discriminative effects of the training dose of THC. However, naltrexone, but not naltrindole or n-BNI, significantly shifted the dose-response curve for THC discrimination to the right. Finally, naltrexone, but not naltrindole or n-BNI, blocked the leftward shift in the dose-response curve for THC discrimination produced by heroin.
CONCLUSIONS: mu- but not delta- or kappa-opioid receptors are involved in the discriminative effects of THC. Given the role that mu-opioid receptors play in THC's rewarding effects, the present findings suggest that discriminative-stimulus effects and rewarding effects of THC involve similar neural mechanisms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15619107     DOI: 10.1007/s00213-004-2118-x

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  45 in total

1.  Functional interaction between opioid and cannabinoid receptors in drug self-administration.

Authors:  M Navarro; M R Carrera; W Fratta; O Valverde; G Cossu; L Fattore; J A Chowen; R Gomez; I del Arco; M A Villanua; R Maldonado; G F Koob; F Rodriguez de Fonseca
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

2.  Stimulus effects of delta(9)-THC and its interaction with naltrexone and catecholamine blockers in rats.

Authors:  T U Järbe; G C Ohlin
Journal:  Psychopharmacology (Berl)       Date:  1977-10-20       Impact factor: 4.530

3.  Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.

Authors:  G Tanda; F E Pontieri; G Di Chiara
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

Review 4.  Relationship between the discriminative stimulus properties and subjective effects of drugs.

Authors:  C R Schuster; C E Johanson
Journal:  Psychopharmacol Ser       Date:  1988

5.  U50,488: a kappa-selective agent with poor affinity for mu1 opiate binding sites.

Authors:  J A Clark; G W Pasternak
Journal:  Neuropharmacology       Date:  1988-03       Impact factor: 5.250

Review 6.  Exploring the opioid system by gene knockout.

Authors:  Brigitte L Kieffer; Claire Gavériaux-Ruff
Journal:  Prog Neurobiol       Date:  2002-04       Impact factor: 11.685

7.  The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys.

Authors:  Zuzana Justinova; Gianluigi Tanda; Patrik Munzar; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2003-12-11       Impact factor: 4.530

8.  Discriminative response control produced with hashish, tetrahydrocannabinols (delta 8-THC and delta 9-THC), and other drugs.

Authors:  T U Järbe; B G Henriksson
Journal:  Psychopharmacologia       Date:  1974

Review 9.  Marijuana's interaction with brain reward systems: update 1991.

Authors:  E L Gardner; J H Lowinson
Journal:  Pharmacol Biochem Behav       Date:  1991-11       Impact factor: 3.533

10.  Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys.

Authors:  J L Wiley; J A Lowe; R L Balster; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1995-10       Impact factor: 4.030

View more
  19 in total

1.  Dopaminergic augmentation of delta-9-tetrahydrocannabinol (THC) discrimination: possible involvement of D(2)-induced formation of anandamide.

Authors:  Marcello Solinas; Gianluigi Tanda; Carrie E Wertheim; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2010-02-24       Impact factor: 4.530

Review 2.  [Future medications for tobacco and cannabis dependence].

Authors:  Bernard Le Foll; Zuzana Justinova; Gianlugi Tanda; Steven R Goldberg
Journal:  Bull Acad Natl Med       Date:  2008-01       Impact factor: 0.144

Review 3.  Human Drug Discrimination: Elucidating the Neuropharmacology of Commonly Abused Illicit Drugs.

Authors:  B Levi Bolin; Joseph L Alcorn; Anna R Reynolds; Joshua A Lile; William W Stoops; Craig R Rush
Journal:  Curr Top Behav Neurosci       Date:  2018

4.  Interactions between μ-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-administration.

Authors:  David R Maguire; Wenjuan Yang; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2013-03-27       Impact factor: 4.030

5.  Open-label pilot study of injectable naltrexone for cannabis dependence.

Authors:  Daniel P Notzon; Meredith A Kelly; C Jean Choi; Martina Pavlicova; Amy L Mahony; Daniel J Brooks; John J Mariani; Frances R Levin
Journal:  Am J Drug Alcohol Abuse       Date:  2018-02-08       Impact factor: 3.829

Review 6.  Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?

Authors:  Patrycja Kleczkowska; Irena Smaga; Małgorzata Filip; Magdalena Bujalska-Zadrozny
Journal:  Neurotox Res       Date:  2016-08-02       Impact factor: 3.911

Review 7.  Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure.

Authors:  Leigh V Panlilio; Zuzana Justinova
Journal:  Neuropsychopharmacology       Date:  2017-08-28       Impact factor: 7.853

8.  Comparison of the discriminative stimulus and response rate effects of Δ9-tetrahydrocannabinol and synthetic cannabinoids in female and male rats.

Authors:  Jenny L Wiley; Timothy W Lefever; Julie A Marusich; Rebecca M Craft
Journal:  Drug Alcohol Depend       Date:  2017-01-11       Impact factor: 4.492

9.  Differential effects of serotonin 5-HT1A receptor agonists on the discriminative stimulus effects of the 5-HT2A receptor agonist 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rats and rhesus monkeys.

Authors:  Jun-Xu Li; Wouter Koek; Kenner C Rice; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2010-01-06       Impact factor: 4.030

10.  Interactions between Δ(9)-tetrahydrocannabinol and heroin: self-administration in rhesus monkeys.

Authors:  Jun-Xu Li; Wouter Koek; Charles P France
Journal:  Behav Pharmacol       Date:  2012-12       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.